BlossomHill Therapeutics Statistics
Total Valuation
BLSM has a market cap or net worth of $443.08 million. The enterprise value is $371.08 million.
| Market Cap | 443.08M |
| Enterprise Value | 371.08M |
Important Dates
The next estimated earnings date is Thursday, November 19, 2026, before market open.
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BLSM has 31.78 million shares outstanding.
| Current Share Class | 31.78M |
| Shares Outstanding | 31.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +5.18% |
| Owned by Insiders (%) | 7.89% |
| Owned by Institutions (%) | 6.14% |
| Float | 17.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.42, with a Debt / Equity ratio of 0.28.
| Current Ratio | 5.42 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -80.79% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.18M |
| Employee Count | 69 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 32.07 |
| Average Volume (20 Days) | 203,324 |
Short Selling Information
The latest short interest is 473,807, so 1.49% of the outstanding shares have been sold short.
| Short Interest | 473,807 |
| Short Previous Month | 137,567 |
| Short % of Shares Out | 1.49% |
| Short % of Float | 2.67% |
| Short Ratio (days to cover) | 2.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -85.24M |
| Pretax Income | -81.60M |
| Net Income | -81.60M |
| EBITDA | -84.74M |
| EBIT | -85.24M |
| Earnings Per Share (EPS) | -$31.83 |
Balance Sheet
The company has $95.38 million in cash and $23.37 million in debt, with a net cash position of $72.01 million or $2.27 per share.
| Cash & Cash Equivalents | 95.38M |
| Total Debt | 23.37M |
| Net Cash | 72.01M |
| Net Cash Per Share | $2.27 |
| Equity (Book Value) | 82.04M |
| Book Value Per Share | -63.15 |
| Working Capital | 82.35M |
Cash Flow
In the last 12 months, operating cash flow was -$70.98 million and capital expenditures -$83,000, giving a free cash flow of -$71.06 million.
| Operating Cash Flow | -70.98M |
| Capital Expenditures | -83,000 |
| Depreciation & Amortization | 504,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -71.06M |
| FCF Per Share | -$2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BLSM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -18.42% |
| FCF Yield | -16.04% |
Analyst Forecast
The average price target for BLSM is $35.40, which is 153.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.40 |
| Price Target Difference | 153.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |